DB:26C

Stock Analysis Report

Executive Summary

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States.


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has NantKwest's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 26C's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-16.0%

26C

-0.7%

DE Biotechs

-0.6%

DE Market


1 Year Return

92.2%

26C

-13.2%

DE Biotechs

-20.9%

DE Market

Return vs Industry: 26C exceeded the German Biotechs industry which returned -12.7% over the past year.

Return vs Market: 26C exceeded the German Market which returned -20.6% over the past year.


Shareholder returns

26CIndustryMarket
7 Day-16.0%-0.7%-0.6%
30 Day-43.3%-8.2%-18.6%
90 Day-31.8%-21.0%-26.2%
1 Year92.2%92.2%-12.9%-13.2%-18.6%-20.9%
3 Year-21.0%-21.0%14.5%13.2%-19.0%-25.8%
5 Yearn/a-9.5%-11.8%-21.2%-31.8%

Price Volatility Vs. Market

How volatile is NantKwest's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is NantKwest undervalued compared to its fair value and its price relative to the market?

2.12x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 26C's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 26C's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 26C is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 26C is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 26C's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 26C is good value based on its PB Ratio (2.1x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is NantKwest forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-13.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 26C is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 26C is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 26C is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 26C's revenue (79.4% per year) is forecast to grow faster than the German market (4% per year).

High Growth Revenue: 26C's revenue (79.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 26C's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has NantKwest performed over the past 5 years?

11.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 26C is currently unprofitable.

Growing Profit Margin: 26C is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 26C is unprofitable, but has reduced losses over the past 5 years at a rate of 11.6% per year.

Accelerating Growth: Unable to compare 26C's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 26C is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: 26C has a negative Return on Equity (-54.52%), as it is currently unprofitable.


Next Steps

Financial Health

How is NantKwest's financial position?


Financial Position Analysis

Short Term Liabilities: 26C's short term assets ($55.8M) exceed its short term liabilities ($11.6M).

Long Term Liabilities: 26C's short term assets ($55.8M) exceed its long term liabilities ($10.9M).


Debt to Equity History and Analysis

Debt Level: 26C is debt free.

Reducing Debt: 26C had no debt 5 years ago.


Balance Sheet

Inventory Level: 26C has a high level of physical assets or inventory.

Debt Coverage by Assets: 26C's debt is covered by short term assets (assets are 3.1388400552911E+16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 26C has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 26C has less than a year of cash runway if free cash flow continues to reduce at historical rates of -29.7% each year


Next Steps

Dividend

What is NantKwest's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 26C's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 26C's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 26C's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 26C's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 26C's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Patrick Soon-Shiong (66yo)

5.08s

Tenure

US$908,746

Compensation

Dr. Patrick Soon-Shiong, M.D., FRCS (C), FACS, MBBCh, MSc, FRCS (C), is an Owner of Los Angeles Times Communications, LLC. Dr. Soon-Shiong is a physician, surgeon and scientist, invented and developed the  ...


CEO Compensation Analysis

Compensation vs Market: Patrick's total compensation ($USD908.75K) is about average for companies of similar size in the German market ($USD757.78K).

Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Patrick Soon-Shiong
Executive Chairman & CEO5.08yrsUS$908.75k61.55% $146.1m
Barry Simon
President13.25yrsUS$1.02m3.39% $8.0m
Sonja Nelson
Chief Financial Officer1.83yrsUS$945.48k0.031% $73.3k
Steven Yang
VP, General Counsel & Corporate Secretary2yrsno datano data
Jerel Banks
Senior Vice President Mergers and Acquisitions4.58yrsno datano data
Leonard Sender
Senior Vice President of Medical Affairs - Pediatric3.25yrsno datano data
John Lee
Senior Vice President of Adult Medical Affairs3.25yrsno datano data
Hans Klingemann
Vice President of Research & Development5.25yrsUS$956.80kno data
Richard Tajak
Consultant1.83yrsUS$288.64kno data

3.3yrs

Average Tenure

66yo

Average Age

Experienced Management: 26C's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Patrick Soon-Shiong
Executive Chairman & CEO5.08yrsUS$908.75k61.55% $146.1m
Barry Simon
President13.25yrsUS$1.02m3.39% $8.0m
Frederick Driscoll
Lead Independent Directorno dataUS$177.43k0.012% $29.2k
Steven Gorlin
Directorno dataUS$169.70kno data
Michael Blaszyk
Independent Director4.75yrsUS$179.97k0.10% $243.6k
John Thomas
Independent Director6yrsUS$179.93k0.26% $605.8k
Cheryl Cohen
Director0.83yrno datano data

4.8yrs

Average Tenure

66yo

Average Age

Experienced Board: 26C's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.1%.


Top Shareholders

Company Information

NantKwest, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NantKwest, Inc.
  • Ticker: 26C
  • Exchange: DB
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$256.056m
  • Listing Market Cap: US$237.339m
  • Shares outstanding: 98.48m
  • Website: https://www.nantkwest.com

Number of Employees


Location

  • NantKwest, Inc.
  • 3530 John Hopkins Court
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NKNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2015
26CDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2015

Biography

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company’s proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/05 08:10
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.